A high density of CD8 T cells, along with increased activity of a specific immune pathway, may help identify which metastatic prostate cancer patients will respond to immune checkpoint blockade (ICB) therapy, according to a report appearing in Science Translational Medicine. ICB has shown promise in treating advanced cancers but tends to be most effective against tumors with high mutational burden since there are neoantigens available for targeting by reinvigorated T cells.